Any meaningful commitment to diversity, equity, and inclusion (DEI) must be considered in the planning stage — not tacked on as an afterthought. Only an intentional and integrated approach will succeed. We will discuss making DEI a priority at the beginning of a trial; barriers to recruiting racially, ethnically, and socio-economically diverse populations; and share strategies for overcoming those challenges to ensure your trial includes and reflects populations that will ultimately benefit from them. 

As an industry, we strive for a diverse, representative population for every trial, seeking to increase patient participation by offsetting burdens with medical value. Yet these barriers to participation are not experienced equally by all socioeconomic groups. Using data from recent patient surveys, this session explores the correlation between socioeconomic status (education, social class, and income), barriers to participation, and patient diversity.

Attend this session to learn how Quest Diagnostics Clinical Trials Solutions works with pharmaceutical organizations to provide data- and infrastructure-based solutions for site and investigator validation and identification, patient recruitment outreach, HCP outreach, DCTs, cohort profiling and analytics, patient-initiated screening (pre-testing), and more.

Mobile health has a significant impact on patient retention and experience in clinical trials. However,it’s still under-utilized as there is a perception that more complex assessments and procedures cannot be conducted effectively in the home. This case study highlights how mdgroup worked with a client to implement complex sample collections in the homes of patients suffering from a rare disease, resulting in reduced travel burden and low dropout rates.

We would like to invite you to join us for an informative event about overcoming obstacles in recruiting patients for BioPharma clinical trials. During this event, we will delve into barriers such as lack of awareness and financial considerations that can impede clinical trial recruitment success. Additionally, impactful strategies to increase clinical trial participation and recruitment success will be shared.

Andrea Valente, CEO of ClinOne, will host an informative presentation examining the role of Adaptive Experiences in clinical trials and how they can provide choice to drive patient compliance and retention. Whether that means using technology at the site, paper at home, or anything in between, it is essential to trust all trial participants (patients, caregivers, sites, and study teams) and empower them to take control of their experience.

Site activation delays, an increase in competitive trials, and study coordinator labor shortages are a few of today’s challenges that are resulting in never-before-seen enrollment bottlenecks at study sites, leading sponsors and recruitment partners to think differently to achieve success.  This presentation will help sponsors maximize their enrollment efforts by identifying and mitigating commonly overlooked metrics in the recruitment funnel that lead to longer enrollment and lower ROI when left unattended. 

Each patient & study have unique challenges & opportunities that require a customised end-to-end approach. Patient needs & perspectives must be the foundation for successful strategy. An in-depth understanding is required to effectively communicate with patients, reduce study burden and meet patients where they are. This session will explore using a holistic approach & collaboration for a highly targeted, strategic recruitment campaign, proactively addressing patient & study needs and increasing enrolment.

Our industry is challenged to find the right resources to drive operational best practice. There is also an expectation to move at the “speed of Covid” for every trial. It feels like an either/or. However, you can have both. You can accelerate timelines with fewer resources. Join this exciting session to learn about: The biggest time and resource drains on clinical trials; Applying AI/ML to improve efficiency; Challenging your own internal processes to get to market faster.

The industry is heading towards a place where digital elements (DCT’s) start to become standard as we operate trials. To achieve scale, and give patients a true choice, digital strategies need to be embedded early into drug development and embraced by sites, patients and sponsors. Join us as we discuss the path to the new normal for everyone in the clinical trials ecosystem.  

The clinical trial industry has been experimenting with Virtual Waiting Rooms (VWRs) in support of patient recruitment and enrollment, but today the use cases vary dramatically and the tools are still in the nascent stages of development. This session examines VWRs across several companies, the challenges VWRs address and current recommendations from early applications.

The industry is looking to new site network models focused on community-based clinics. By being embedded in the community, new site networks may be able to increase patient recruitment & convenience, improve retention, & enhance diversity in clinical trials. We will discuss strategies and ways non-traditional site networks could transform the clinical trial delivery model.

No matter what method is used, the goal of informed consent remains the same – to properly inform patients as efficiently and effectively as possible. In this session, we’ll explore how to use technology to improve the consent experience for sites as well as participants, regardless of whether it’s in the clinic, living room, or both.